The submitted manuscript is drafted by experts in the field that have performed the preclinical work and know how to describe and support their work. It is informative and can impact on both clinical and pre-clinical scientists.
The submitted manuscript is a succinct, balanced and informative description of the preclinical work that led to the initiation of a phase IIb trial investigating the clinical benefits of the use of S44819 (a GABA α5 inhibitor) in cases of stroke.
I find that this work fulfils its role and I only have minor points that I would like to see addressed:
1) The authors should comment and discuss in some detail about the absence of side effects after the treatment with S44819. Even if this drug acts upon extrasynaptic GABA receptors it is expected to affect control/ contralateral tissue; this was shown by the TMS study in healthy humans. Are there any signs from the preclinical work that show such an effect? What is the expectation/ extrapolation for its clinical use?
2) The authors should discuss in a little bit more informative way the comparison between the effects of treatment with S44819, erythropoietin and neural progenitors after stroke. Apart from the time-scale of appearance and duration of the effects, it would be important to have their comparative evaluation regarding histological and behavioural effects (e.g. neural progenitors showed effects at the contralateral side, too).
